High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma

dc.creatorBaldissera, R.C.
dc.creatorAranha, J.F.P.
dc.creatorOliveira, G.B.
dc.creatorVigorito, A.C.
dc.creatorEid, K.A.B.
dc.creatorMiranda, E.C.M.
dc.creatorDe Souza, C.A.
dc.date2002-01-01
dc.date2014-07-17T15:05:01Z
dc.date2015-11-26T11:25:25Z
dc.date2014-07-17T15:05:01Z
dc.date2015-11-26T11:25:25Z
dc.date.accessioned2018-03-28T20:39:23Z
dc.date.available2018-03-28T20:39:23Z
dc.identifierBrazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 35, n. 1, p. 49-57, 2002.
dc.identifier0100-879X
dc.identifierS0100-879X2002000100007
dc.identifier10.1590/S0100-879X2002000100007
dc.identifierhttp://dx.doi.org/10.1590/S0100-879X2002000100007
dc.identifierhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002000100007
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/24187
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/24187
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1233338
dc.descriptionTrials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin's lymphoma (NHL) (60.6%) or persistent or relapsed Hodgkin's disease (39.4%) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin's disease) followed by autologous PBPC transplantation. On an intention to treat basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10(6)/kg (1.07-29.3) CD34+ cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15%, respectively (P<0.0001). Overall survival was 92% for chemosensitive patients and 0% for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12% (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin's disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin's disease, with acceptable mortality rates related to sequential treatment.
dc.description49
dc.description57
dc.languageen
dc.publisherAssociação Brasileira de Divulgação Científica
dc.relationBrazilian Journal of Medical and Biological Research
dc.rightsaberto
dc.sourceSciELO
dc.subjectMalignant lymphomas
dc.subjectHigh-dose cyclophosphamide
dc.subjectAutologous peripheral blood progenitor cell transplantation
dc.subjectSalvage therapy
dc.titleHigh-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución